The deal gives Novo exclusive rights to use Nanexa’s PharmaShell platform to develop long-acting injectable treatments across five development programmes targeting obesity, type 2 diabetes and other cardiometabolic diseases.
Nanexa could receive up to €1.165 billion, including €615 million in upfront and development and regulatory milestone payments. The remaining milestones are linked to sales. In addition, Nanexa will receive a low single-digit royalty on future global net sales.
BREAKING